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Abstract for Senior Proj ect 
11-19-01 
The Vascular Research Laboratory Experience 
In the summer of2001, I worked in a Vascular Research Laboratory (VRL). This senior 
project attempts to give a holistic approach to the experience by revealing three areas: 1) An 
overview of the VRL at The University of Tennessee Hospital in Knoxville 2) A summary of 
basic laboratory techniques learned 3) A paper on the research and experiments I performed this 
summer. 
The VRL works in direct contact with the 'Division of Vascular Surgery to study new 
techniques and solutions to problems encountered during surgery. The laboratory also exists as 
part of the curriculum for fellows, residents, and graduate students, as well as an educational 
laboratory for undergraduate students interested in research and/or medicine. 
Mastering basic laboratory techniques creates the foundation of any researcher. The 
VRL emphasizes cell and tissue culture, cell morphology, gel electrophoresis, protein assay, 
immunohistochemistry, protein isolation, aseptic technique, densitometry, and butTer 
formulation. An attempt is made in the paper to acquaint a researching neophyte with these 
techniques to ease the transition and shorten the time introducing these procedures when needed. 
The actual research and experiments accomplished this summer comprises the last 
segment. An emphasis is placed on isolating smooth muscle cells from other cell types in the 
artery, especially from the fibroblasts, using fluorescent techniques. This project hypothesizes 
that fluorescent labeling might provide a faster and less expensive way to collect pure human 
aortic smooth muscle cells at low passages. An overview of a heat shock protein (HSP-70) 
project studying HSP-70 expression in canine arterial endothelial cells at different localized fluid 


















The Purpose of the Vascular Research Laboratory 
at the 
University of Tennessee Graduate School of Medicine 
The Vascular Research Laboratory at the University of Tennessee Graduate School of 
Medicine is supported through the Surgery Department at the University of Tennessee Hospital. 
The premise is to work in collaboration with the vascular surgeons at the hospital on ideas and 
problems associated with vascular surgery. The laboratory's efforts are based around "rigorous, 
basic and translational research in the biology of the vascular system" (Mission Statement). The 
laboratory focuses on the necessary understanding of cellular interactions and mechanisms in the 
peripheral vessels to better treat vascular disease medically and/or surgically. The Vascular 
Research Lab is dedicated to training talented surgeons in "experimental design, basic and 
advanced cellular techniques, pre-clinical biomedical device evaluation and scholarly 
presentation of experimental data" (Mission Statement). Inclusion of outside investigators, 
graduate students and undergraduate students is considered a strength of the program as it 
introduces non-surgical perspectives which encourage creative solutions and challenge 
assumptions to solve complicated problems. 
The main functions of the lab are as follows: 1) research and training of select surgical 
residents and vascular fellows, 2) :support of clinical research and development projects, 3) basic 
support research and clinical projects requiring technical expertise in tissue and cell 
cryopreservation, cell isolation and cell culture, retroviral insertion of genes into endothelial 
cells, fluorescence activated cell sorting (F ACS) and analysis, protein isolation and Western 
blotting, RNA isolation and Northern blotting, PCR, immunohistochemistry, histologic 










As a Student Assistant in the Vascular Research Lab at UT Hospital in Knoxville, 
Tennessee, I learned many basic techniques that create the foundation of any researcher. An 
emphasis was placed on cell and tissue culture, cell morphology, gel electrophoresis, protein 
assay, immunohistochemistry, protein isolation, aseptic technique, densitometry, and buffer 
formulation. Several of these topics were covered in this section in order to acquaint a 
researching neophyte with these techniques. The desire was to ease the transition and shorten the 
time introducing these procedures when needed. 
CELL CULTURE 
Introduction: 
_ Cell culture using sterile technique is the process of freezing, unfreezing, growing, and splitting 
specific cells in media compatible for the cells. Sterile work with the cells always occurs in a 
- laminar flow hood where the airflow, temperature, and equipment are contained. Cell containers 






Freezing Cells Back: 
When freezing cells back, media is aspirated off the cells and buffer is added and aspirated to 












cells from the flask or well, taking about 5 minutes. Gentle tapping or incubating may quicken 
the releasing of the cells from the flasks. Once the cells have lifted off of the flask, media with 
serum is added to stop the enzyme trypsin. The cell solution is transferred to a tube and 
centrifuged in a balanced centrifuge for 5 minutes at 1500 rpm. The supernatant is aspirated 
from the tube and the pellet is re-suspended in 0.9mls fetal bovine serum (FBS) and O.lml of 
dripped DMSO and the solution is put in a cryovial. The cryovial is placed in a step-down cryo-
preservation container which is then placed in a -80 degree Celsius freezer. The following day, 
the cryovial is removed from the freezer and placed in liquid nitrogen. The location of the 
cryovial in the liquid nitrogen must be logged. The hood should be sprayed with 70% ethanoL 
Unfreezing Cells: 
When tmfreezing cells, the specified cryovial is taken out the nitrogen tank, and put in a warm 
water bath. The cryovial must remain standing, and water must not cover the top of the vial 
because the cap is porous with the potential to compromise sterility if contacted by water. Once 
unfrozen, the vial should be sprayed with 700/0 ethanol excluding the cap. The cells are then 
diluted in the desired amount of media and put into the appropriate flask(s). The media must be 
changed the following day. The hood should be sprayed with 70% ethanol. 
Growing Cells: 
- Growing cells are contained in flasks or wells, depending on the desired amount and usage. 
-
-
They are kept in incubators that maintain a temperature of37 degrees Celsius and a pressure of 
5.0 atm Nitrogen, which optimizes growth. Cells must be kept in media that is best for the type 








Inc, St. Louis, MO), SMGM2 (Smooth Muscle Growth Media, Clonetics), DMEM (Dulbecco's 
Modified Eagle's Media), and EGM (Endothelial Growth Media), and all include 10 % FBS . 
Splitting Cells: 
When splitting cells, the cells are typically confluent from growth in a flask. Media is aspirated 
off the cells, and CMF is added and aspirated to wash the remaining media from the cells and the 
container. Trypsin, using half of the amount of media used to grow the cells, is added to strip the 
attached cells from the flask or well, taking about 5 minutes. Gentle tapping or incubating may 
quicken the stripping. Once the cells have lifted off of the flask, media with serum is added in 
the same amount as the trypsin. The cell solution is transferred to a tube and centrifuged in a 
balanced centrifuge for 5 minutes at 1500 rpm, (Notice, this is the same procedure as that for 
freezing cells back thus far). The supernatant is aspirated from the tube and the pellet is re-
suspended in a volume or media divisible by the split. For instance, if splitting the cells into 3 
different flasks, the pellet may be re-suspended in 3 mls of media. The media should be spread 
all over the side growing the cells to insure equal growth throughout the flask. The flasks should 
be labeled appropriately with a change of passage number and placed in the incubator. The hood 

























The tissue is embedded in paraffin. The embedded tissue is secured in a J ung histocut. The 
tissue is angled in the holder so that the embedded block is perpendicular and parallel to the 
razor to minimize wasteful cutting and to insure the entire tissue is cut in each slice. Sharp razors 
should be used at all times during the cut to ensure clean cuts, so safety is extremely important. 
A safeguard should be placed on the razor at all times the histocut is not being used, or the razor 
should be removed. Anytime the embedded tissue is not being cut, especially when positioning 
the tissue, the wheel should be in a locked position. Most tissue cuts have a thickness between 4 
and 6 micrometers. The tissue is cut in bands with a manually-controlled wheel. If the tissue is 
not cutting well, the tissue and paraffin can be frozen with an aerosol freezer and/or hydrated 
with water. Once several cuts have been made insuring that the entire section is included, the 
bands are transferred to a water bath of 40 degrees Celsius. Fixation solution can be put in the 
water to aid in mounting on the slides. Each slide is angled in the water bath to pick up a slice of 
the embedded tissue. The slide is allowed to dry. The slide is placed on a hot plate to melt the 
paraffin. The slide(s) are placed in slide books to await the desired staining. Typical stains 
include H and E (Hematoxylin and Eosin) to stain the cytoplasm and nucleus, Smooth Muscle 
Alpha Actin to stain smooth muscle cells, antibody additions for adhesion, and quadrochrome to 














Most protein measurements do not have to be sterile. The protein measurements include protein 
isolation or extraction, protein assay, and Western blotting using gel electrophoresis. 
Protein Isolation: 
Using a nuclear and cytoplasmic extraction kit, non-denatured proteins can be purified in less 
than two hours. Protease inhibitors as well as Cytoplasmic and Nuclear extraction Reagents 
(CER and NER) (Pierce Co., Rockford, II) are made in the specified concentrations. CER I is a 
hypotonic solution so that cells swell. CER II is a detergent that makes holes in the cells so that 
the intracellular components excluding the nucleus exit the cell membrane. NER is added 
causing the cell to shrink and nucleus to exit the cell mernbrane. NER is only needed if nuclear 
proteins are desired. 
Homogenizing tissue: 
1 ml of PBS is added to each specimen. 2 tubes are filled with 50 ml of isopropyl alcohol and 2 
tubes are filled with de-ionized water. The homogenizing blade is washed in a tube of de-
ionized water. The tissue is then homogenized, which is simply grounding the tissue so that it is 
well mixed. The blade is then washed with water, alcohol, and then PBS. The steps can be 
repeated as needed for each speci.(l1en. Once all of the specimens are homogenized, they are 
centrifuged at 1,000 G's for 5 minutes. 1.5 ml microfuge tubes are labeled appropriately. 100 ul 
of CER I plus some extra is obtained for each vial. Protein inhibitors are added to the CER I in 
the correct concentration, as noted in the extraction kit. The new CER I solution is kept on ice. 
Before adding the CER I to the specimens, the supernatant is taken off of the centrifuged tubes. 
The pellet is resuspended in 0.5 ml of PBS and transferred to smaller vials. The new vials are 
.. 
- centrifuged at 500 G's for 2 minutes. The supernatant is aspirated, and 100 ul of the chilled CER 













seconds. The new solution is incubated on ice for 10 minutes. After incubation, 5.5 ul CER II is 
added to each viaL The solution is vortexed again for 5 seconds on the highest setting. It is then 
centrifuged for five minutes at the highest setting. The tubes are then put on ice. The 
supernatant, which is the cytosolic protein, is extracted and stored quickly. Care is taken not to 
get too close to the pellet. 
Protein Assay: 
U sing a protein assay kit and the Lowry procedure, protein specimens can be measured against a 
standard. The goal is to generate a graph of absorbance versus concentration against the 
standards. Protein standard solutions are made using the given directions in the protein assay kit 
and vials are labeled appropriately. The concentrations are typically the following: 
Standard # Protein concentration Protein Standard Solution Water (ul) 
(uglul) (ul) 
1 a 0 1000 
2 5 125 987.5 
3 10 25 975 
4 25 62.5 937.5 
5 50 5 875 
6 100 250 750 













Mixtures are made with 10 uls of each sample and 990 uls of water. Starting with the least 
amount of water concentration needed, the water is added for the standards and then the correct 
amount of water is added to the samples. Next, 1 ml of Lowry's Reagant is added to every tube 
including the standards and the samples. Each tube is vortexed at minimum speed and then sit 
for 20 minutes. While vortexing for quick and imnlediate mixing, 0.5 ml of folin is added. The 
solutions sit for 30 minutes and the spectrophotometer is turned on. All the solutions are then 
taken to the spectrophotometer. On the spectrophotometer, the quantitative route is chosen, and 
parameters are changed to print the seven standards, and concentrations are entered. Then, 1 rrtl 
of water is added to each cuvet, and auto-zero is pressed. The cuvets should be placed such that 
the clear sides face sideways and the rippled sides face the front and back. Care should be taken 
not to touch the cuvet on the flat, clear sides so that the results are not skewed. The front cuvet is 
discarded and 1 ml of each solution is added, going through the standards first, using a new cuvet 
each time. The results are printed with a graph of the standard to insure there is a small deviation 
from the expected results, and a table reportin"g the unknown concentrations of the protein 
samples. The desired mass is typically around 30 ug. In order to obtain the desired amount of 
mass from each sample, the desired mass should be divided by the concentration, and the 
quotient is the volume needed for ~ach sample to have that mass. Sometimes, samples must be 
re-concentrated because the amount is too small or large for the desired masses. 
.. Microconcentrators with filters are used. Frozen vials are thawed and 90 uls of each sample is 















Project: Isolating Aortic Smooth Muscle Cells via Fluorescent Markers 
Background: 
Current techniques to sort aortic smooth muscle cells from arterial tissue are both 
expensive and inefficient. The current method available physically sorts the smooth muscle 
cells, and the only one available for the University of Tennessee at Knoxville is at the Veterinary 
School. 
This experiment attempts to test a possible alternative to current methods of obtaining 
pure lines of smooth muscle cells by chemically labeling smooth muscle cells and fibroblasts . 
Using Levamisole and Vector Red (Vector Lab Inc, Burlingame, CA), an attempt will be made 
to use these fluorescent markers as flags to sort the smooth muscle cells from the artery. If 
successful, this method would be useful in identifying and then obtaining the smooth muscle 
cells separated from the rest of the artery. Not only would it be cheaper, but sorting could be 
accomplished easily in any lab. 
Experiment: 
Canine Fibroblasts (K9 Fibro) and Human Aortic Smooth Muscle Cells (HuAOSMC) 
were pulled from the storage freezer and grown separately in T-25 and T-75 flasks in Dulbecco's 
Modified Eagle's Media (DMEM) and Iscores Modified Dulbeccos's Media (IMDM), 
respectively. Once confluent, (and the fibroblasts were confluent much sooner), the cell lines 
were each plated in wells at varying concentrations (see table below). These solutions were then 
each tested with Vector Red and Levamisole to determine the best concentration for viability and 
fluorescence of the cells with the markers. 
--
Vector Red was made using one drop of the A, B, and C alkaline phosphotase droppers 
for every 2.5 mL of 100mM Tris-HCL. 1 mL of this new solution was mixed with every 9 mLs 
of PBS. The final solution was then filter sterilized using a syringe and a .02 micron filter with 














Vector Red reacts with light and is less sensitive the longer the final solution sits. 
The Levamisole solution was made using 2 drops of Levamisole per 2.5 mLs of 100 mM 
Tris-HCL. 
When checking for toxicity and flow, the amounts used with the fibroblasts were as follows: 
Cells Treated with Vector Red 
Well Concentration Amount Vector Red Amount Media 
1 100 2ml Oml 
2 1 :10 200 ul 1.8 ml 
3 1:100 20 ul 1.98 ml 
4 1:500 4 ul 1.996 ml 
5 1 :1000 2 ul 1.998 ml 
6 Control (0) Oml 2ml 








Well Concentration Amount Levamisole Amount Media 
1 1:25 80 ul 2 ml 
2 I 1:50 40 ul 2 ml 
3 1:100 20ul i 2ml 
4 1:200 10 ul 2ml 
15 1:400 5 ul 2 ml 
6 2:25 160 ul 2 ml 
Note: The control used in the wells treated with Vector Red also served as the control for the 
wells treated with Levamisole . 
After 16 hours of incubation with the mixed solutions, the wells were observed under 
_ microscopes to get approximations of dead cells which look rounded and/or floating versus 
viable which are flat and attached to the plate. The following observations were made: 
- Cells Treated with Vector Red 
- Well Concentration of solution Approximate Percent dead 
-
(floating) 
1 1000/0 90% 
-
2 1:10 10% 
-















4 1:500 <1% 
5 1 :1000 <1% 
6 Control (0 0/0) <1% 
It should also be noted that Wells 5 and 6 appeared to have more dead cells because of 
over-confluency. 
Well Concentration. of solution Approximate Percent dead 
(floating) 
1 1:25 10% 
2 1:50 50/0 
3 1:100 <5% 
4 1:200 <5% 
5 1:400 <1% 
6 2:25 90% 
It should be noted that wells 1-5 follow a decreasing concentration pattern, while well 6 
had the highest concentration of Levamisole. 
The cells from each well were then counted with a Hen10cytometer using protocol VRL-
SOP-607 (Vascular Research Lab-Standard Operating Procedure-607). Each of the 6 wells were 




for five minutes at 1500 rpm's. They were each re-suspended in 1 ml of media (DMEM). Using 
Trypan Blue the cells were counted. 
The remaining cells treated with Vector Red were then tested in flow conditions with a 
histogram by means of a FACS machine, (Fluorescent Activated Cell Sorting machine). First, 
they were re-centrifuged for five minutes at 1500 rpm's. The supernatant was aspirated and the 













Human Aortic Smooth Muscle Cells were also grown in two 6-well plates in SMGM2 
(Smooth Muscle Growth Media 2) and when confluent, where treated with Vector Red and 
Levamisole in the following concentrations: 
Cells Treated with Vector Red 
Well Concentration Amount Vector Amount Media 
Red (SMGM2) 
1 1:10 200ul 1.8 ml 
2 1:40 50 ul 1.95 ml 
3 1:200 10 ul 1.99 ml 
4 1:400 5 ul 1.995 ml 















[ Control (0) 
Cells Treated with Levamisole 
Well Concentration I Amount Amount Media 
Levamisole (SMGM2) 
1 1:40 50 ul 1.95 ml 
2 1:200 10 ul 1.99 nl1 
3 1:400 5 ul 1.995 ml 
4 1:1000 2 ul 1.998 ml 
5 1:1 :100 10 ul Vector Red 1.98 ml 
10 ul Levamisole 
6 Control (0) Oml 2 ml 
It should be noted that wells 5 and 6 were accidentally mixed. 
After sixteen hours, the dead cells and viable cells were counted using Trypan Blue and a 
Hemocytometer using Standard Operating Procedure VRL-SOP-607 . Each well was trypsinized 
by aspirating the media, washing in CMF, aspirating the CMF, releasing with 1 ml of trypsin, 
and diluting in 1 ml SMGM2. 25 uls were taken of each sample in a 1.5 ml tube and 500 ul 
Trypan Blue and 475 ul CMF were added to the 25 uls of cell media. A cover slip was placed on 
top of a clean, dry hemocytometer. Approximately 10 ul of the suspension was added to each 
-- side of the hemocytometer. The cells were then counted using a given formula. Only cells 
inside the lines counted, and blue ones reflect non-viability. The following results were found: 
-
- Cells Treated with Vector Red 
.. 
Well Concentration Viable Non-viable 





3 1:200 10,000 0 
14 1:400 10,000 0 
-
5 1:1000 30,000 10,000 
6 Control (0) 20,000 20,000 
-
-
- Cells Treated with Levamisole 
Well Concentration Viable Non-viable 
.. 
1 1:40 10,000 10,000 
-
2 1:200 20,000 30,000 
3 1:400 10,000 0 
-
4 1:1000 10,000 20,000 

















I Control (0) 1 10,000 
Note: These Smooth Muscle Cells did not grow very well. However, the cells were counted in 
10,000 increments. When taken to F ACS, the machine did count almost 5000 cells for each of 
the wells. 
All of the remaining solution of cells, trypsin, and SMGM2 was re-centrifuged at 1500 
rpm's for 5 minutes. The supernatant was aspirated, and the pellet was re-suspended in 1 ml of 
1 % PBS. The cell-suspended solution was taken to F ACS. 
The results using the F ACS machine from the canine fibroblasts and the human aortic 
smooth muscle cells were compared. First it was noted that Levamisole and ·Vector Red 
fluoresced specific cells similarly. This showed that one fluorescent marker did not prove more 
favorable to either fibroblasts or smooth muscle cells. It was decided that Vector Red would be 
the fluorescent marker studied from this point. 
The three fluorescent band pass filters, i.e. FL 1, FL2, and FL3, fluoresced best at 530 nM 
for FITCIFL1, 585 nM for PIIPE or FL2, and greater than 650 for RedIFL3. It was also noted 
that the Vector Laboratories repoI1ed that Vector Red excitation is "broad and seems to be from 
360 run to 560 run," while the emission spectrum seems to be above 560 run. 
For every concentration level, the canine fibroblasts fluoresced with one sharp peak just 
less than 101 and ending around 102• The human aortic smooth muscle cells, on the other hand, 
fluoresced with two peaks around 102 and 103• The most intriguing finding was that at a Vector 




















the FL2 and FL3 with peaks halfway between 102 and 103 as well as 103 and 104. These results 
are not only higher than the fibroblast emissions, but do not even overlap. Thus, the possibility 
of gating the cells at 102 or slightly above could result in a pure smooth muscle cell line. 
Due to availability and unavailability of specific cell lines, cells were grown in 8 wells. 
The first two contained rabbit fibroblasts, the second two contained canine fibroblasts, the third 
two contained human smooth muscle cells T IG A TCC, and the fourth two contained human 
fibroblasts which was confinned after a negative alpha actin staining test for smooth muscle 
cells. The rabbit fibroblasts and canine fibroblasts were grown in DMEM, the human smooth 
muscle cells were grown in SMGM2, and the human fibroblasts were grown in IM:DM. One of 
each of the types of wells was considered a control, to which only media was added, and the 
other had 200 ul of Vector Red to 1.8 ml of media, a concentration of 1 :10. The cells were 
incubated for sixteen hours. Upon retrieval they were centrifuged, the supernatant was aspirated, 
and the pellet was re-suspended in Imll % PBS. The canine fibroblasts, wells 3 and 4, did not 
grow very well. It was assumed that they were grown for several days in media without 10% 
FBS, thus killing the cells. 
The results showed the rabbit, canine, and human fibroblasts peaking between 101 and 
102 and tapering quickly above 102. The fibroblast peak completely ends by 103. The human 
smooth muscle cells, on the other .hand, peaked above 103, with an ascending slope sharpening 
halfway between 102 and 103, and remaining high until 104. A mild peak with the smooth 













The goal is to efficiently and inexpensively isolate smooth muscle cells from arterioles so 
that the cost of future research using smooth muscle cells will be reduced, and the availability of 
smooth muscle cells will be increased . 
Heat Shock Protein Project 
Atherosclerosis is a progressive vascular disease causing plaque formation and an 
ensuing occlusion of the vessel lumen. The disease begins with endothelial lesions. It has been 
documented that endothelial lesions result from several local hemodynamic factors such as wall 
shear stress and turbulent flow. It has been reported that adhesivt:! properties of endothelial cells 
are heightened by chronic shear stress. In response to high shear stresses in both in-vivo and in-
vitro models, endothelial cells increasingly express heat shock proteins (HSPs). In direct 
correlation, studies have shown the enhanced adhesive properties would benefit from vascular 
graft implantation. Potentially, HSPs are targets of anti-HSP antibodies at primary endothelial 
lesion sites for decreasing auto-immunogenic activity. A transplant may be at risk of "arterio-
venosclerosis" or post-implantation sclerosis if exposed to arterial hemodynamic conditions, 
which is relevant to the use of vein grafts. 
The goal of this project was to study HSP-70 expression in canine arterial endothelial 
cells at different localized fluid s~ear stress conditions. Endothelial lesions at the beginning of 
atherosclerosis would be better understood ifHSP-70 expression was upregulated with those 
stress conditions. Using native blood and artery of a canine, the expression ofHSPs could be 
tested in an ex vivo model. An in vitro study occurred using media with the same viscosity as 
blood. This study included a flow apparatus allowing two vascular conduits to be exposed 










molecules including adhesion molecules, could be done using this as a model. The ability to use 
native blood in the flow system makes the model as close to an in vivo model as possible while 
keeping other hemodynamic factors independent. 
In the ex-vivo model, cells from the carotid arteries of dogs were exposed simultaneously 
to different flow conditions via a flow system. Each vessel was exposed to each condition and 
compared. The conditions included normal physiological stress at 15-30 dynes/cm2 and extra-
physiological stress anywhere above 60 dynes/cm2. Blood was the fluid used at a time constant 
of four hours. Distributive analysis was done for intima, media, and adventia layers of the vessel 
using immunohistochemical staining. The staining compared the amount of HSP-70 expression 
in each layer. Difficulty was encountered cutting the grafts as tissue for slide preparation because 
the grafts were plastic. Protein analysis was also done to quantify the amount of protein in the 
endothelial cells. Two static controls were used. The first static control remained at room 
temperature for four hours before they were frozen. The second static control was tissue placed 
in a petri dish with whole blood in an incubator at 37 degrees Celsius with 5 percent carbon 
dioxide. The staining of the tissues is in progress and is part of on-going research in the 
Vascular Research Lab. 
The Flow System: 
A 2000 ml Erlenmeyer flask was filled with media and a stop cork was used with holes 
for the gas-permeable tubing. A pulse dampener and pulsitile pump were used to pump blood 
into the system. Ti-Cron suture was used to tie the vessels to the connectors. 25 ml pipets were 
used to keep the vessels straight and stable because curvature would skew the results. The flask 
was incubated in water at 37 degrees Celsius to be comparable to human body temperature. A 
trial run was done using ~ater . 
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1 of 3 
. .'. This SOP will be followed by personnel engaged in research and clinical studies in 
the Vascular Research Laboratory of the Department of Surgery. 
Purpose: 
To describe the procedures for proper splitting of cells 
3. 
Reagents Required 
a. Clonetics trypsinJEDTA (stored frozen in sliver freezer) 
b. CNIF (in hood) _ 
c. Media with serum (in white refrigerator) 
d. 70% Ethanol (next to hood) 
Equipment Required 
a. 10 ml pipette 
b. Centrifuge tube 
c. Appropriate number ofT-75 flasks 
d. Aspirator -' 
e. Pipettes 
Operation Guidelines 
a. Turn the hood on at least 10 minutes prior to beginning. 
b. Place the Clone tics trypsinlEDT A, CNIF, and media with serum in the 
hood and spray with 70% Ethanol. 
c. Place the cells in the hood. 
d. Aspirate the media off the cells. 
e. Place 5 ml of CNlF on the cells and slide around flask to cover cells 
completely. 
f. Aspirate the CNlF off the cells. 
. - -- .~ 
- -- -~ 
- . - .. - -'~ 
i-
--I --
- ~ , --
r-
SOP University of Tennessee Page 
Number lViedical Center 
Vascular Research Lab Of 
VRL-SOP 2 of 3 
601 
. ~ , 
Standard Operating Procedures 
g. Place 5 ml of trypsinJEDT A on the cells. 
h. Allow the cells to come off the surface of the flask for about 5 minutes. 
Watch cells under microscope, tapping gently helps get all of the cells off 
the surface. 
1. Once the cells are off the bottom of the flask, add 5 ml of the media with 
serum to the flask. 
J. Use a 10 ml pipette to pull all of the solution out of the flask to transfer to 
a 15 ml centrifuge tube. DURING SUCTION INTO 10 NIL PIPETTE, 
THE CELLS ARE NOT TO EXCEED THE COTTON PROTECTION 
ON THE TOP OF THE PIPETTE. IF THIS OCCURS, THE STERILITY 
OF THE CELLS HAS BEEN CON1PROMISED. 
k. Spin the cells in the centrifuge at 1500 rpm for 5 minutes. MAKE SURE, 
CENTRIFUGE IS BALANCED. (:r.(\'\c~,) ~c:.v'(~-
(S~ nt.L.J i-1S t\c,.~~~ ~+~pe ,.;,P (ell; ~,c," / uf'-,r ;,, ',tl·.;.I<;/ dc..+e/u)kc..t ;la ,,) 
1. Once the cells have spun, place the tube' back in the hood and aspirate off 
the supernatant. BE CAREFUL NOT TO ASPlRA TE THE PELLET IN 
THE BOTTOM OF THE TUBE. 
m. Bring the cells up in a volume suitable for the size of your split with 
media. (i.e. 3 mls for a 1:3 split, etc.) 
n. Place the correct amount of cells in a T -75 flask. 
o. Add the remainin81~olume of media to have 10 mls of media in the flask . 
Spf'e.:::.d ""ed; I:tO V \!-J ) ~ Jc 
p. Label the flasks and change the passage number. Loosely replace lids and 
place flasks in the incubator. 
q. Clean up hood/working area with 700/0 ethanol. 
~,,',' - . . Trouble shooting 
,' a. If at any point during the procedure, the sterility of the cells are 
compromised, the cells are to be ~i~posed off or lab_el~~ _~s being 
SOP University of Tennessee Page Number lVledical Center 
VRL-SOP 
Vascular Research Lab Of 
601 Standard Operating Procedures 
3 of 3 
b. contaminated until further instructions for course of action from the lab 
supervIsor. 
c. To avoid such problems, the user should sterilize the hood/working area 
with 70% ethanol before starting the procedure. 
d. Be careful not to aspirate the pellet in the bottom of the tubes. 
S. Calibration Instructions 
.NA 
6. Routine Maintenance Instructions and Schedule 
NA 
7. Non-routine maintenance instructions 
NA. 
8. Responsible person(s) 
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University of Tennessee 
iVledical Center 
Vascular Research Lab 
Standard Operating Procedures 
Title: Freezing Cells Back :.-li 
scope:i; 
This SOP will be followed by personnel engaged in research and clinical stucll.es in 
1. 
the Vascular Research Laboratory of the Department of Surgery. 
II. Purpose: 
To describe the procedures for proper freezing of cells back. 
III. Procedures: 
1. Reagents Required ., .;~ . , ;.~ 
a. TrypsinlEDT A (frozen in silver freezer) 
b. C1v[f (in hood) 
~ Media with serum (in white refrigerator) .' 
( c, / d. Aliquot of FBS (frozen in sil ver freezer or \.~ ....... .I.~~~~~~~~:...~';.,';.~J.. 
P~ .. ~'<>,,) e. DMSO (in hood in a foiled 15ml tube) 
2. 
3. 
f. Thawed Mr._Frosty (frozen in -80°C freezer at the end of hall) 
g. 70% Ethanol (next to hood) 
Equipment Required 
a. lSml centrifuge tube 
b. Iml-c)'fev-i-RI ~rL'~f"'.A.\ 
c. Icc syringe 
d. Aspirator 
e. 10ml pipette 
Operation Guidelines 
a. Tum on the hood at least 10 minutes to beginning. 
b. Spray the hooclJwor-king area with 70% Ethanol. 
,":;; :"~~ c ... \ K-c...Q.l '-'I ~_ ~(,<..2J 
c. Place FBS in water bath until thawed, then place in hood. 
d. Place trypsin/EDTA, CMF and media with serum in hood aftt~~~'J.:l 
a-teefto1. 
e. Place cells in hood and aspirate the media off the cells. 
_. -- - _._._ .. - - -+----
r· 
~- .-
1-- . . 
\-.. -_. -
-4------
.- .. - - ' -.---+-- _. '-' - - .-
. . . .. ,_ .. -. - -+-----
SOP 
Number 
University of Tennessee 
lVIedical Center 




Standard Operating Procedures 
f. Place 5 ml of CN1F on the cells and slide around tlask to cover cells 
completel y. 
g. Aspirate the CN1F off the cells. G) ('A~ ') PL I ,i\ ,.\ <- vl:-":,'\'C: 
h. Place 5 ml of trypsinJEDT A on the cells. GI""') ~r:: "{C, L-~21: He: t-" c.elil , t .,;V;)I'~ J 
-t- .c,dd, J..:~ ' l":...I·c" c; ~- f r~)~IA 
1. Allow the cells to come off the surface of the t1ask for about 5 minutes. 
Watch cells under microscope, tapping gently helps get all of the cells off 
the surface. L ) .. L '~ ' I " I' ~ " ~' 
. _ \ .. ~ ... ' G1--~ c.dl t"\ oc *L:.. ;(.u:\.tc fLiP::' Jr I'1t'1; ", (.~ l-v.: ') 1r~- 'j ,,1 W.(o.~ 
')'-) ~r~CA. . .,1 / / 
l '" t· e, \ i 1\ ; ~ \ "'- I ) 
J. Once the cells are off the bottom of the t1ask, add 5 ml of the media with 
serum to the t1ask. I ,,\~\'1 c--.j..}, \Q) 
.""L.. 
K. Use a 10 ml pipette to pull all of the solution out of the flask to transfer to 
a 15 ml centrifuge tube. DURING SUCTION INTO 10 NIL PIPETTE, 
THE CELLS ARE NOT TO EXCEED THE COTTON PROTECTION 
ON THE TOP OF THE PIPETTE. IF THIS OCCURS, THE STERILITY 
OF THE CELLS HAS BEEN C01v1PROMISED. 
1. Spin the cells in the centrifuge at 1500 rpm for 5 minutes. MAKE SURE 
CENTRIFUGE IS BALANCED. 
m. Once t0e cells have spun, place the tube back in the hood and aspirate off 
the supernatant. BE CAREFUL NOT TO ASPIRATE THE PELLET IN 
THE BOTTOM OF THE TUBE. . w \,.-V. \, JlS f 
.):"} ~ f"'l 
,\ " III " , .c S \ "" ~ 
..... \. ~ J 
I " \ 
n. Resuspend the pellet in 0.9 mls of FBS and place in the cryovial. ~- 'Y '~ ') 
tJf)<:,_ ..:\ fT';d.: p;pd'" 
o. Bbt2till 2t l-~c syringe and place 0.10 cc ofDMSO into the vial, dripping it 
slow ly over the cells. (tco . u.L) 
p. Label the cryovial appropriately, place it into the Nlr. Frosty, and put in 
the -800 C freezer at the end of the hall. 
q. The next day, remove the Mr. Frosty from the freezer and place the 
cryovial in liquid nitrogen. Fill out the liquid nitrogen log book so the 
location of the cells are appropriatel y documented 
- ' SOP University of Tennessee 
Medical Center 














a. If at any point during the procedure, the sterility of the cells are 
compromised, the cells are to be disposed off or labeled as being 
contaminated until further instructions for course of action from the lab 
supervIsor. 
b. To avoid such problems, the user should sterilize the hood/working area 
with 70% ethanol before starting the procedure. 
c. Be careful not to aspirate thejJellet in the bottom of the tubes. 
Calibration Instructions 
NA 
Routine Nlaintenance Instructions and Schedule 
Alcohol in the Mr. Frosty should be changed after 5 uses. Allow the Mr. 
Frosty to thaw after remQving from the freezer. 
Non-routine maintenance instructions 
NA 
8. Responsible person(s) 
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JE-PERTNI Nuclear and 




J NE-PERTM Nuclear and Cytoplasmic Extraction Reagents 
3747 N. Meridian Road 
PO. Box 117 
Rockford, IL 61105 
0872w 
This kit supplies a complete set of lysis reagents that enable the separation of nuclear extract and 
cytopla,smic fractions from cultured cells and tissue. The optimized reagents and protocol allow 
non-denatured, active proteins to be purified in less thanlwo hours. This kit contains sufficient 
cytoplasmic and nuclear extraction reagents for extracting 50 cell pellet fractions with a packed 
cell volume of 20 III (a total of -2.0 g of cell paste). 
Kit Contents 
Cytoplasmic Extraction Reagent I (CER 1), 10 mL 
Cytoplasmic Extraction Reagent II (CER Il), 550 JlL 
Nuclear Extraction Reagent (NER), 5 mL 
,nstructions for Use 
:\ 'erials 
Mammalian cells from whole tissue or cultured cells 
B. Protease inhibitors: 
Nuclear and cytoplasmic extraction can be done without the use of protease inhibitors. For optimal results, 










,.. TO 0 0 
. following protocol reflects reagent volumes based on samples with a packed cell volume of appro ximately 20 ~ (--40 
mg of cell paste). Determine the packed cell volume (or mass) of your samples. then substitute volumes as indicated in the 
table below. 
Packed Cell Volume CERI CERII NER 
10 III (20 mg) 100 III 5.5 III 50 III 
20 III (40 mg) 200 III II III 100 III 
50 III (100 mg) 500 III 27 .5 III 250 III 
100 III (200 mg) I ml 55 III 500 III 
Note: All centrifugation procedures should be done at 4°C. Keep cell samples and extracts on ice . 
Telephone: 800-8-PIERCE (800-874-3723) or 815-968-0747 • Fax: 815-968-7316 or 800-842-5007 
I nternet: http://www.piercenet.com 
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:)'11 \ - 2 'J-D - c~r2 '7 '0 
Jo :1 i: .J:.. (? 0 ? rnPiERCE 
I. Isolate 20!J.l packed cell volume (40 mg) of cells by centrifugation in a 1.5 mJ microcentrifuge tubt: by centrifugation at 
500:< g for 2-3 minutes. Note: If using tissue samples, cut the tissue into small pit:ces, add an appropriate buffer such 
as PBS, and homogenize in a tissue homogenizer. Pellet the cells by centrifugation at 500 :\ g for 2-3 minutes and 
remove the supernatant. Estimate the packed cell volume, add the appropriate amount of CER I according the chart on 
page I, and continue with Step 4 below. Alternatively, weigh the tissue, cut it into small pieces, dounce homogenize 
directly in CER I. and proceed to Step 4. Use a 10-fold excess of CER lover tht: wt:ight of tissue (t:.g. 500 ~I CER I to 
50 mg tissue) . In Step 5 of the protocol, use 5.5 ~I ofCER II per 100 ~I orCER l. 
2, Using a pipet, carefully remove and discard the supernatant, leaving cell pellet as dry as possible. 
3. Add 200 ~ of ice-cold CER I to the cell pellet. 
4. Vortex vigorously on the highest setting for 15 seconds to fully resuspend the cell pellet. Incubate the tube on ice tar 10 
minutes. 
_I 5. Add 11 ,w of ice-cold CER II to the tube. 
~---'---.- . -- - ---, 
Vortex 5 seconds on the highest setting. Incubate on ice for I minute, 6. 
7. Vorte:< 5 seconds on the highest setting. Centrifuge the tube for 5 minutes at maximum speed in a microcentrifuge 




Immediately transfer the supernatant (cytoplasmIc extract) fraction to a clean pre-chi1l8d tube. Place this tube on ice. 
Resuspend the insoluble (pellet) fraction produced in Step 7, which contains nuclei, in 100 !J.l of ice-cold NER. 
Vortex on the highest setting for IS seconds. Return the sample to ice and continue vortexing for 15 seconds every 10 
minutes, for a total of 40 minutes. 
I!. Centrifuge the tube at full speed (\6,000 x g) in microcentrifuge for 10 minutes. 
12. Immediately transfer the supernatant (nuclear extract) fraction to a clean pre-chilled tube, Place on ice. 
13 . Store all extracts at -80°C until use. 
Troubleshooting GUI e 
Observation Possible Causes What to do 
Low cytoplasmic protein yield 
-" 
Cells not lysed Increase amount of CER II Reagent 
Cell pellet not dispersed Vortex thoroughly 
Low nuclear protein yield Cell pellet not dispersed Vortex thoroughly 
Incomplete nuclei isolation Increase time of centrifugation 
following addition of CER II 
Low concentration of protein Volumes of extraction reagents not Adjust volumes as directed in protocol 
appropriate for given packed cell table of reagent volumes based on 
volume packed cell volume 
No .o.r, ~o~ protein activity detected Samples not kept cold Centrifuge at 4°C and keep samples on 
: .' oJ C 4 • ice between vortexing steps 
.~ ~ 11' :' E?resence of proteases Use suggested protease inhibitor 
'"'I~'li "' cocktail 
Proteins not compartmentalized Incompl~t~ re~oval of cytoplasmic Carefvlly remove all cytoplasmic 
.. .1. extract · ' " extradt prior to nuclear lYSIS 
\ Incomplete lysis of cells Increase vortexing time to be sure cd I 
pellet is dispersed 
No or low protein yields in either Cell line dependent result May not work with all cell lines 
fraction 
Su .. ~ ;- i", 





Micro BCATM Proteih Assay Reagent Kit 
SuperSignalOO West ?ico Chemiluminescent Substrate 
~Pierce Chemical Co. [011999 . Printed in the U.S.A. 
Telephone: 800-8-PIERCE (800-874-3723) or 815-968-D747 • Fax: 815-968-7316 or 800-842-5007 
Internet: http://www.piercenet.com 
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K9 #4 Protein IsolationlExtraction 
S122/01 
Static 0 hrs--7mm total length after thawing 
11 111 11 ----1
1 Static 4 hrs--l0mm " 
Normal 4 hrs--17mm " 
Extraphysiological 4hrs-- 12mm 
1. For static sections, approximately half of total length was used for the PI procedure. 
2. Transferred the sections to separate SOm! c§ntrifuge tubes (in ice) 
3. Added 1m! PBS to each tube. 
4. Homogenized each section 
S. At each interval, washed the homogenizer blade with D-water, isopropyl alcohol and PBS respectively 
6. Centrifuged tubes @ 1000G for S minutes 
7. Extracted supernatant and resuspended in O.Sml PBS. 
8. Transferred solution to appropriately labeled 1.Sml microfuge tubes (in ice) 
9. Made SOO uL CER I solution and added luL benzamidine, 0.5 uL Aprotinin, 0.5 uL Leupeptin and 2.S 
uL PMSF and vortexed to mix well. 
10. Added 100uL of CER I to each microfuge tube and vortexed for IS seconds at highest setting 
11., Incubtede for 10 minutes on ice. 
12. Added S.S uL of CER II to each tube. 
13. Vortexed for S sec, incubated for 1 minuted, vortexed again for S secs 
14. Centrfuged for S minutes at 16000Gs 
IS. Labeled and put four O.S ml microfuge tubes into ice. 
16. Transferred the supernatanat which was the protein to O.S ml microfuge tubes 
17. Got about 100uL of protein in from each tube. 
. 
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t... IN~OCUCT10N 
;rwry procedure has been tcund to be the mas: retiabla 
;hr:::::=.ry mctrlod fer ql.Im"ICibcian of ~1.Jbte prtJtl!!in:s. The 
~ Jescribed here is basad on Per.arson'6' modilicatiJn 
~ rru:thod ~ utiIiz:e:s sodium dodecytsulfuca. 
ttla ~rt ReacJ2t'It. to fac:iliQta d1a ~cion of 
, ~8 lipoprotz:ris.' 
ilnv pr-oc:aios. t:t11l l...oNry ract:ion an be N1 din:c:!y on 
solucion. HOIM!Vet". inrarterenca in th8 direct lDwry 
I cau.5IId by c:crnrnr:ny used chemic::aJ.s. .ru::h as Tris. 
fate. SJ'TA. su::I"'OSQ. citnlCR, ilTli10 acid lW'ld ~ 
!nd phen~. The proc:edure \.\lith pror.ain pracpiQcion. 
;~ DOC (d~ 1 ~ 11:A (tric:hJon::Iace acid]. 
\ ~ l1lase irn:arferencas with C"le ~gpcion of ph.nclL 
e emount at ~ proc:eiro.s recovered ttv"OlJgh me 
3tZ1J m{1'( very dapencfir,g on the p8I"ticJJar pl"OfZlti 
. ."pRINCZPLE 
i/inl! cupric i:Zrtnsc. ~.~ comp/el%:3 witM the oe:acide 
, ... 'orms a DlJr"pIe-Olu.sil OJlor wh8l'l d1a phenol re.lSgent 
sorbence ~ reed ac a Slitabie wavelengtl"l b~en 
800 nm. The prco:in ~ ~ detennined 
raoon curve.. l 
FaLIN & ClOCALTEU'S PHENOL. REAGENT 
WORKING SOLUTION is oreOCln:d try tran:5terring c.h'e 
concanc:s (1S mJJ of FaUn & Cioc:ait.eu's Phenol ~gent aJ 
the amboer gla:s:s b~ provW:l sd for the WOli<ing Sotution. 
!=linn the Folin &. Ciocaltau'6 Ptlenol Reagenc bcm::a wirt110 
mI aaionized water and add rin:sing:s IlJ Woricing Solution 
bca:1e.. Add an additional SO mI aeionized wacer OJ ene 
W~ Solution boc::1e end mix well. St:cr"l! Fain & 
Coclt.eu·. Ph.no! l=Iugane WoMci1g Solution ilt: room 
~p.r.iCJra 
~RC'T'SN STANDARC, Caallog No. P 7656 
from boW1a SiIt'I.IITI altJumin. tracc:on V (BSAl. 
PRcnlN STANDARC SOLUTION, 4CC pg/mt. i:s 
prepared by edding to the 'Jial the 'JOluma of wacer indbt2d 
en tN '.IiOIl ~bti. Swirl ganay to completely ~lve. Stt:re 
scan:icn in ens re~er<!tor (0-80q or ~ (below O·C). 




(Without P.-atein PM!cipit:adon] 
* 1. Pr-eoare STANDARO TUSS by d~utin.g Prorz:in Standard 
-.,ae. SOtuccn with w8O!r IlJ a volume of 1.0 rnI in acpropr;l:IO:ly 
-/'-~laOaJed !:eSt woes: 
c: "rvc..,n . Pr_ .. 
r\~ Sbnd~ SolutIOn w.~... c... ...... na-ull." 
(_...Q,,n..l... (m,! ("...) (,,'31,..,41 
...,.------------------- -:s r 1:.:.C-- \, / 0.12'5 0.97:: 50 
~EAGENTS 
(for laboratory use only. 
t: far drug. household or O1:her uses.) 
. Cr::AGENT, MOOIRED, cacaJog No. L 1013 
CORs:10SIVE. Avoid concact wic.h P:ye~. sKIn 
. 00 noc breamQ dust:. 
VRY REAGCNT SOWTlON Is prepared try adding 40 
oJ8'tl!r to a boC1:le crt l..J:N.Jry I=\eage~ Modified. Mix well 
l' '--eng to compj~ly d1s~M:. 00 not. sheke :so a~ OJ 
~ foaming . Sdueion ilO SClb~ ;oc room ~mperd~. 
TREFRlGERATE 
lwnON, Cat;3log No. 0 5525 
! OUlO :solution crt :sodium de.mycholac.e. 1.5 mglml. 
Q OACETlC ACIC ' SOWTlON (TeA). 
T 4396 
:JUS solutior\ of cric:Horoe~tic acid, 72% w/v. 
l' r,ORROSrvE. CAUSES BURNS. Avoid COf1~c: Wlcn 
xl cJochin<). 
IOCALTEU'S PHENOL J:lEAGENT, 
No. F 9252 
~; r-:OnROSIVE. CAUSES BURNS. Avoid concnc::: with 
r . r:luLhillg. '00 'noe bniocJ'C vnpor. _ ' ._ .. 
Z 0.250 0.750 100 
7 0.500 O.~ClO 2Go 
-"l G.750 0.250 ::;00 
S 1.000 a 400 
\ 2 . lAbel II ~ tube 8L6.NK and Ildd 1.0 rnl ~r.cr: 
-5t'.> 3. Add !tample to appropria~ labeled CZIiC rube lind dilut.e co 
V... . 1.0 mj witn waE:2r: .\) 4. Add 1.0 rnl LO-..vry Fieag~t:. Solution co STANoAFiD. 2LANK and S:'MP1..E Cubes. Mix well. 
5 . Allcw '~Olutions to 5~ a-c. roam C2mper3tu~ fer 20 
mtnuc.es. 
6. With rapid and irnmediilE:2 mixing. aaa 0.:: mt Faun & 
Cic::c<llt:eu 's Phenol ReaQent: Working Solution 1:0 each cube. 
7 . AIIO'N co1or to develoo for 30 minuc.e5. 
8. Transfer soluoons c::J a..wetS and meastJre d1e absorbance 
of cr.e STANDARDS and SAMPLE wbe~ v:s. the BLANK at: 
a wcve~gd1 between sao 3r-d 800 11m. Comp/et.e {"I!oding' 
wicllin 30 minuc.es. 
9. Ploe. Cl1e absorbance values of me STANDAROS lIS. chelr 
corr--Stlonding prat.ein concentJ'"lltJCns to prepa~ 0 C3IIbrllc:i01 
au-va. (S~e Figunl 1 tor a t;ypiC<l1 calibration cur--e for 
Gcandards aC 750 rlm.J 
10. Oec.errnine cne protein concentration of the SAMPLE 0 
from u-.a c.alibnlcion Ct.J/"".Ie. MuJtiply the rr:~lt bv 
apt:rOpriat.: dlLticn facr:a- aJ obc:nin the protein concer 
in t:.he original snmple. 
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PRODUcr SPECIF1CATION SHEET 
HUMAN FIBRONECIlN 
Fibronectin is a broad range natural cell adhesion factor. It is a 440-500 kDa dimeric glycoprotein consisting of two 
similar 220-250 kDa subunits linked by two disulfide bonds. It is found a3 a dimer in plasma and in multimeric form 
in the extracellular IIl3.tI'U and on cell surfaces. Its primary function is related to cell adhesion to the extracellular 
matrix which occurs via the Arg-Gly-Asp-Ser (RGDS) sequence of fibronectin with the appropriate transmembrane 
integrin receptor of the cells.! Other domains of fibronectin are also involved with this adhesion process and may 
involve in1eraction with collagen. heparin and other ~ll surface glycosaminoglycans. J The conforc.ation and 
orientation of adsorbed fibronectin is also important and has an effect on ceU spreading and strength of adhesion of 
endothelial ceUs.1 Fibronectin ad.dition_to_~_free medium promotes cell adhesion J More significant effects..ar .... e ____ _ 
observed with BHK. CHO and other cell lines by coating of cultureware with fibronectin at 1-5 uglcnr. Details of 
fibrooectin structure. properties, distribution, cellular expression. interaction with other proteins, matrix properties, 
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FIBRONECTIN, Human 
354008 LOT NUMBER: 001760 
Human plasma' 
NOTE: The source plasma WlIS tested and found nonreactive for hepatitis B 
surface antigen (HB.Ag) and negative for antibody to human 
immunodeficiency· ?frus (HIV). Nevertheless, this product should be 
handled using the same safety preca~oos used when handling potentially 
infectious material. 
1 milligram per vial, lyophilized. 
100 mM CAPS, 0.15M NaO. 1 mM calcium chloride, pH 11.0. 
Equilibrate vial to room temperature. Resuspend in one milliliter sterile distilled 
water. Allow 30 minutes for material to go into solution. DO NOT AGITATE 
OR SWIRL. If entire amount of material is not to be used immediately, 
transfer into appropriate aliquOlS and store at -20"C. It is recommended that 
solubilized product is used within two weeks. DO NOT srORE IN FROST-
FREE FREEZER. AVOID MULTIPLE FREEZE THAWS. 
Human Fibronectin is generally used in the concentration range of 1-5 
micrograms per cm1 of growth surface for attachment or at 5 micrograms per mi 
as a me'dia additive. 
Please see reverse for coating directions . 
440,000 in non-reduced form. 
Becton Dickinson Labw3re 
Two Oak Park 
Bedford, MA 01730 
(781) 275-(0)4 Fax: (781) 275-0043 
(800)343-2005 
.· .. :~.~-:-:.-:- :.n;·::.:. : . 
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.2:.. 99% by 4-12 % SDS-PAGE under reducing conditions. 
Human Fibronectin has been tested for its ability to promote attachment and 
spreading using BHK-21 cells. 
Fibronectin has been tested and found negative for the presence of bacteria, fungi 
and mycoplasma. 
Stable for a minimum of 3 months from day of shipment when stored at 2-8°C. 
1. Aota, S., et.al., 1. BioI. Chern., 266:15938 (1991). 
>------·----------------i::---iWtftft6::--f:7+:-:--et:-:!!b.*"Biom~Mater. Res. , 21.1103 (l993). 
i 
I 
3. Bames, D., and Sato, G., Cell, 22:649 (1980). 
4. Hynes, R.O., Fibronectins, Springer-Verlag, New York (1990). 
5. Mosher, D.F. (ed), Fibronectin. Academic Press, New York (1989). 
Coating Procedure 
Use these recommendations as guidelines to deteImine the optimal coating conditio os for your culture system. 
,1) .. :...... Dilute fibronectin to desired concentration using serum-free cu1ture Ca++, Mg++ free medium or buffer 
at pH 7-9. The final solution should be sufficiently dilute so that the volume added will cover the surface 
evenly. 
Example: If the final coating concentration will be 5 ug/cm1, dilute the materi3J. to 50 ug/ml and add 1 
m1J35 mm dish, 3 mU60 mm dish, etc. 
NOTE: Because of the CAPS component in the HFN preparation, buffers of media containing Ca H 
andIor Mg++ added to..@e HFN may result in the formation of insoluble metal hydroxides. This will not 
occur if the buffering capacity of the diluent brings the pH to 8.0 or lower. 
2) Add appropriate amount of diluted fibronectin to culture surface. 
3) Incubate at room temperature for 1 hour. 
4) Aspirate remaining materia1. 
5) Rinse plates carefully with dHlO - avoid scraping bottom surface. 
6) Plates are ready for use. They may also be stored at 2-8"C damp or air dried if sterility is maintained. 
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
354008 rev 1.0 Release Date: 5/14/99 LOT NUMBER: 001760 
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SOP University of Tennessee Page 
Number . lYledical Center 
Vascular Research Lab 1 of 3 
VRL-SOP.307 
Standard Operating Procedures 
Title: H&E staining of paraffin embedded tissue slides 
I. Scope: 
This SOP will be followed by personnel engaged in research and clinical studies in 
the Vascular Research Laboratory of the Department of Surgery. 
II. Purpose: 
To describe the procedures for regressive hematoxylin and eosin histochemical 





a. 1 % acid alcohol 
b. Ammonia water 
c. Working eosin solution 
d. Hematoxylin stain 
e. 100% ethanol 
f. 95% ethanol 
cr Xylene (9r equivalent) o· 
Equipment required 
a. Solution containers (staining boats). 
b. Multi-well slide staining station . 
c. Exhaust fume hood. 
Protocol Guidelines 
a. Deparaffinize and hydrate tissue to deionized H20 (VRL.SOP. ) 
b. Stain in Richard-Allen II hematoxylin for 1 minute at room temperature 
(RT). (Harris hematoxylin substituted for 12 minutes at RT is an acceptable 
substitution) 
c. Rinse in tap water until glass is clear. 
d. Differentiate by dipping 5-10 times in 1 % acid alcohol. 
e. PI.ace in ammonia water to blue. «10 sec) 
f. Rinse in warm running water for 30 sec. 
g. Place in 80 % Alcohol for 1 min. 
h. Place in 1 % working eosin for 30 sec. 
1. Serially place in 3 changes of 95 % Alcohol for 30 sec each change . 
j. Place in absolute alcohol for 1 min. 
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SOP University of Tennessee Page 
Number Medical Center 
Vascular Research Lab 2 of 3 
VRL-SOP.307 
Standard Operating Procedures 
k. Clear in 3 changes of Xylene for 2 min each change. 
1. Coverslip with Pennount and coverslip in fume hood. 
4. Expected results 
a. Nuclei stain blue 
b. Erythrocytes stain reddish pink 
c. Cytoplasm stains pink 
S. Calibration Instructions 
Study pathologist will approve acceptability of staining quality 
6. Routine Reagents needed for working reagents solutioftS 
a. Deionized H2O 
b. 100 % ethanol 
c. Ammonium hydroxide (VRL.SOP.20 ) 
d. Stock eosin solution (VRL.SOP.20 ) 
7. Routine working solution maintenance 
a. Alcohol station solutions should be changed every twenty-one days 
b. Ammonia water station solutions should be changed after 5 uses. 
c. Hematoxylin solution should be filtered every third day or if 
crystallization is observed. 
8. Trouble shooting 
a. Hematoxy1i~ solution contains crystals: filter hematoxylin using FisherR 
filter paper. 
b. Nuclear staining is too intense: incrementally increase differentiating in 
acid alcohol solution. ' 
c. Nuclear staining is too pale: incrementally increase hematoxylin staini-ng 
time. 
d. Cytoplasmic staining is too intense. Incrementally decrease staining time 
in eosin working solution. 
e . . Substitution of this procedure by automated staining (subcontracted 
outside lab) is acceptable . 
9. Responsible person(s) 
Laboratory director / laboratory supervisor 
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This SOP will be followed by personnel engaged in research and clinical studies in 
the Vascular Research Laboratory of the Department of Surgery. 
Purpose: 






a. All r..eagents used to split cells (refer to VRL.SOP.601) 
b. Trypan Blue 
Equipment required 
a. All equipment required to split cells (refer to VRL.SOP.601) 
b. Hemocytometer, cover slips 
Operation Guidelines 
a. Follow steps 3a-31 from cell splitting procedure (refer to VRL.SOP.601) 
b. Resuspend cells in one ml of media. 
c. In a 1.5ml tube, add 500111 Trypan Blue, 475111 of C'NfF and 25111 of the 
media. 
d. Dry hemacytometer anti place coverslip on top. 
e. Add approximately 20 III of suspension into both sides of hemacytometer. 
f. Calculate the cell count using the equation: cells/ml = (n) x 104 , 
where n = the average cell count per square of the four corner squares 
counted. For example: cells/ml = (n) x 104 or cells/ml = 30 x 10,000 = 
300,000 cells/ml. 
g. Cells that land on the outside the lines, do not count. All cells on the 
inside of lines count. 
h. Cells that take up the plue color are dead and they do not count. 
4. Trouble shooting 
Same as VRL.SOP.601 
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Standard Operating Procedures 
5. Calibration Instructions 
NA 
6. Routine Reagent 
NA 
7. Responsible person(s) 
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Vector® Red Alkaline Phosphatase Substrate Kit I 
Cat. No. SK-5100 
The Vecto~ Red substrate kit contains all of the reagents necessary (except buffer) to prepare_ 
solution for either immunocytochemical or membrane-based applications. Vector® Red nrr)rl' -Irf'<:'li' 
reaction product that can be seen using either brightfield or fluorescent microscopy. V 
pennanently mounted in non-aqueous media or mounted aqueously in VECTASHIELD® 
DISPENSING REAGENTS: 
For convenience, the reagents are supplied in dropper bottles. When dispensing drops, hold 
inverted vertical position and squeeze gently. To prevent evaporation, secure the opaque 
when they are not in use. DO NOT PIPET REAGENTS DIRECTLY FROM BOTTLES. 
each component may be different due to solvent characteristics. Proper concentrations of ___ l __ ~ __ ;C:"_" 
components in the working solution are assured only by -using the drop dispensers. 
INSTRUCTIONS FOR USE: 
Prepare the Vecto~ Red substrate working solution immediotely before use. 
1. To 5 ml of 100 mM Tris-HCI, pH 8.2 - 8.5 buffer*, add 2 drops of Reagent l. 
2. Add 2 drops of Reagent 2 and mix well. 
3. Add 2 drops of Reagent 3 and mix well. 
,.. This kit contains a modified formulation to improve stability. It is important to make 
solution in 100 mM - 200 mM Tris-HCI buffer, pH 8.2 - pH 8.5 
Incubate tissue sections or membranes with substrate solution at room temperature until 
develops. Development times should be determined by the investigator but generally 
provides good staining intensity. Improved staining may be obtained by developing the sUI)st.lra!!~ 
Wash sections in assay buffer for 5 minutes. Rinse in water. 
For pennanent mounting: Rinse in tap water, counterstain, if desired (see chart on reverse), 
and mount in a pennanent mounting medium, such as VectaMount "", Catalog No. H-5000. 
For aqueous mounting in VECf ASHIELD® Mounting Medium : Tap excess buffer Tr(),rTT"'<!P('til1.na, 
Before mounting, slides may be rinsed for 2-5 minutes in 100% ethanol to increase the 
Red fluorescence. 
The Vecto~ Red reaction product is a highly fluorescent, non~fading, bright red precipitate 
with Texas Red® or rhodamine excitation and emission filter systems. Vector® Red t1uore~scl~nc:~l:J 
visible with fluorescein or AMCA filter systems using broad band emission filters. 
NOTES: 
1. Use the working solution of Vector® Red within 15 minutes of preparation or decreased 
result. Increasing the incubation time in substrate solution beyond 45 minutes will not' 
sensitivity, unless freshly made substrate solution is reapplied to sections. 
2. Do not heat Vector<» Red substrate kit components or working solution. Heating decreases 
3. The reagents should be stored at 4 °C and protected from light whenever possible. 
precipitate may fonn in some reagents upon prolonged storage. This will have no effect 
or intensity of the staining. Do not fi!ter the reagents or working solution. 
4. Do not put sodium azide in the buffer used for the Vector® Red working solution; it will 
5. For tissue, using 0.1 % Tween® 20 in the Vecto~ Red working solution may increase the 
crispness of staining especially when non-enzymatic qntigen retrieval methods are used 
staining protocol. Tween<» 20 should not be added to the Vector» Red substrate solution 
applications. 
6. When using neural tissue, Vector» Red is not recommended for visualizing processes, 
(inadequate staining may occur). 
7. Endogenous alkaline phosphatase activity (other than the intestinal isoenzyme) can be 
addition of levamisole (Cat. No. SP-5000) to the buffer prior to the preparation of the 
Intestinal alkaline phosphatase activity can be inhibited, before immunostaining, with 
pretreatments (Bulman AS and Heydennan E; 1. Clin. Pathol. 34, 1349-1351,1981). 
IMPORTANT: Little is known about the toxicity and carcinogenicity of the substrate 
Care should be taken in the handling and disposing of all the reagents. 
Tween" 20 u a re!JiJlered trrukmark. of Allm ClumicaJ IndUJln .. 
T.~ R,a" IJ a re!JiJI,red lrademarl< of Mokcular Prob .. Inc. 
Vector laboratorie~ ... JD~., 30 Ingold Road, Burlingame, CA 94010 U.S.A., • (650) 697-3600 • 
- ------- ------
--- ----- - -----,.:,. 
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Concentration 125 mM 
Levamisole Solution 
Cat. No. SP-SOOO 
-----I:.J - Storage Refrigerate 
--------: 
REMARKS: 
Levamisole will inhibit most forms of alkaline phosphatase other than the intestinal isoenzyme. 
Since the intestinal form of the enzyme is used as the marker enzyme in the VECTASTAIN® 
ABC-AP Kit, levamisole can be used to inhibit endogenous alkaline phosphatase in most cases. 
Because the inhibition produced by levamisole is reversibler-the inhibitor must be added to the 
substrate solution. 
This lot of levamisoie was tested on two frozen tissues and was found to completely 
inhibit endogenous alkaline phosphatase activity. 
INSTRUCTIONS FOR USE: 
When used in conjunction with Vector Laboratories' Alkaline Phosphatase Substrate Kits, add 
one drop of Levamisole solution to 5 ml of alkaline phosphatase substrate buffer and mix well. 
Then add substrate reagents and continue as outlined in the instructions for the Alkaline 
Phosphatase Substrate Kit. ~ 
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Vector Laboratories [vector@vectorlabs.com] 
Thursday, July 26, 2001 3:20 PM 
- Donnell, Robert L. 
Re: Vector Red Excitation and Emission Levels 
Thanks for your email and phone inquiry from Frances Kirkland. The 
ex}stgiclpn is broad and ~eems to be from 1&9pm tQFRuah to 56PMi. The 




----- Original Message 
From: "Donnell, Robert L." "~I1.II.iiii ••••• '-
To: <vector@vectorlabs.com> 
Sent: Thursday, July 26, 2001 11:35 AM 
Subject: Vector Red Excitation and Emission Levels 
> We currently use your Vector Red Alkaline Phosphatase Substrate Kit 
and 
are 
> wondering what the excitation and emission wavelengths on the Vector 
Red 
> Stain are. 
> Sincerely, 
> 
> Robert L. Donnell, DVM, PhD 
> Director of Surgical Research 
> Department of Surgery, UTMCK 
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File: FIB/SMC 8/3/01.001 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: TAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G 1 Gated Events: 4730 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4730 100.00 94.60 74.74 50 
M1 1, 132 4221 89.24 84.42 49.88 50 
M2 132, 8582 514 10.87 10.28 279.42 142 
Histogram Statistics 
File: FIB/SMC 8/3/01.001 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: TAG= TUBE Ac:9uisition Date: 3-Aug-1 
Gate: G1 Gated Events: 4730 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4730 100.00 94.60 84.97 42 
M1 1, 132 4104 86.77 82.08 50.87 42 
M2 132, 8582 634 13.40 12.68 306.27 198 
Histogram Statistics 
File: FIB/SMC 8/3/01.001 
Patient 10: ;rAG = TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 4730 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4730 100.00 94.60 73.68 27 
M1 1, 132 
M2 132, 8582 
4162 
573 
87.99 83.24 43.92 
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FIB/SMC 8/3/01.002 ~--------------------~ 
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File: FIB/SMC 8/3/01.002 Sample 10: FIBROBLAST VECTOR REO 
Patient 10: TAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G1 Gated Events: 4548 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4548 100.00 90.96 97.73 47 
M1 1, 132 3782 83.16 75.64 61.34 47 
M2 132, 8582 780 17.15 15.60 274.79 132 
Histogram Statistics 
File: FIB/SMC 8/3/01.002 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
A~quisition Date: 3-Aug-1 
Gated Events: 4548 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4548 100.00 90.96 116.37 61 
M1 1, 132 3603 79.22 72.06 64.43 61 
M2 132, 8582 955 21.00 19.10 312.50 137 
Histogram Statistics 
File: FIB/SMC 8/3/01.002 
Patient 10: 'TAG= TUBE 
Gate: G1 
Sample 10: .FIBROBLAST VECTOR REO 
Acquisition Date: 3-Aug-1 
Gated Events: 4548 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4548 100.00 90.96 98.14 40 . 
M1 1, 132 3779 83.09 75.58 53.88 40 
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File: FIB/SMC 8/3/01.003 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: TAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G 1 Gated Events: 462 
Total Events: 750 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 















File: FIB/SMC 8/3/01.003 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: TAG= TUBE A~uisition Date: 3-Aug-1 
Gate: G1 Gated Events: 462 
Total Events: 750 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 462 100.00 61.60 476.76 37 
M1 1, 132 310 67.10 41.33 55.94 37 
M2 132, 8582 152 32.90 20.27 1335.03 195 
Histogram Statistics 
File: FIB/SMC 8/3/01.003 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: rAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G1 Gated Events: 462 
Total Events: 750 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 462 100.00 61.60 383.66 13 
M1 1, 132 324 70.13 43.20 43.01 13 
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File: FIB/SMC 8/3/01.004 
Patient 10: TAG=TUBE 
Gate: G1 
Total Events: 720 
Histogram Statistics 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 360 





All 1, 9910 
M1 1, 132 
M2 132, 8582 
File: FIB/SMC 8/3/01.004 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 720 
360 100.00 50.00 
178 49.44 24.72 
767.09 
52.28 





Sample 10: FIBROBLAST VECTOR RED 
A~quisition Date: 3-Aug-1 
Gated Events: 360 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 360 100.00 50.00 813.38 
M1 1, 132 176 48.89 24.44 54.67 
100 104 

















File: FIB/SMC 8/3/01.004 
Patient 10: !fAG= TUBE 
Gate: G1 
Total Events: 720 
Marker Left, Right Events 
All 1, 9910 360 
M1 1, 132 187 
M2 132, 8582 173 
Sample 10: FIBROBLAST VECTOR REO 
Acquisition Date: 3-Aug-1 
Gated Events: 360 
% Gated % Total Mean Peak Ch 
100.00 50.00 690.35 21 
51.94 25.97 43.71 21 
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File: FIB/SMC 8/3/01.005 
Patient ID: TAG= TUBE 
Gate: G1 
Sample ID: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 3740 
Events % Gated % Total Mean 
3740 100.00 74.80 2073.54 
418 11.18 8.36 46.06 






File: F1B/SMC 8/3/01.005 
Patient ID: TAG= TUBE 
Gate: G1 
Sample ID: FIBROBLAST VECTOR RED 
A~uisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 3740 















File: F1B/SMC 8/3/01.005 Sample ID: FIBROBLAST VECTOR RED 
Patient ID: 1"AG= TUBE Acquisition Date: 3-Aug-1 
Gate: G 1 Gated Events: 3740 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 3740 100.00 74.80 1703.18 1370 
M1 1, 132 469 12.54 9.38 37.92 11 
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File: FIB/SMC 8/3/01.006 
Patient 10: TAG = TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 2785 
Events % Gated % Total Mean 
2785 100.00 55.70 1129.67 
599 21.51 11.98 48.53 






File: FIB/SMC 8/3/01.006 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
A~quisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 2785 
Events % Gated % Total Mean 
2785 100.00 55.70 1463.40 
355 12.75 7.10 78.96 






File: FIB/SMC 8/3/01.006 
Patient 10: TAG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 
M2 132, 8582 
Gated Events: 2785 
Events % Gated % Total Mean 
2785 100.00 55.70 1318.56 
407 14.61 8.14 77.28 
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File: FIB/SMC 8/3/01.007 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3766 
M1 1, 132 3218 
M2 132, 8582 558 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 3766 












File: FIB/SMC 8/3/01.007 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3766 
M1 1, 132 3355 
M2 132, 8582 418 
Sample 10: FIBROBLAST VECTOR RED 
A~uisition Date: 3-Aug-1 
Gated Events: 3766 
% Gated % Total Mean Peak Ch 
100.00 75.32 80.35 50 
89.09 67.10 54.73 50 
11.10 8.36 286.82 141 
Histogram Statistics 
File: FIB/SMC 8/3/01.007 
Patient 10: ifAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3766 
M1 1, 132 3544 
M2 132, 8582 221 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 3766 
% Gated % Total Mean Peak Ch 
100.00 75.32 53.28 38 
94.11 70.88 39.06 38 
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File: FIB/SMC 8/3/01.008 Sample 10: FIBROBLAST VECTOR RED 
Patient 10: TAG= TUBE Acquisition Date: 3-Aug-1 
Gate: G1 Gated Events: 4648 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean 
All 1, 9910 4648 100.00 92.96 228.75 
M1 1, 132 2295 49.38 45.90 76.34 






File: FIB/SMC 8/3/01.008 
Patient 10: TAG=TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
A~quisition Date: 3-Aug-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 132 























File: FIB/SMC 8/3/01.008 
Patient 10: FfAG= TUBE 
Gate: G1 
Sample 10: FIBROBLAST VECTOR RED 
Acquisition Date: 3-Aug-1 
Gated Events: 4648 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1,9910 4648 100.00 92.96 172.75 90 
M1 1, 132 
M2 132, 8582 
2539 
2128 
54.63 50.78 78.87 
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File: HUSMC'S 7 
Patient 10: TAG= 
Gate: G1 
T etal Events: 50 
Marker Left, Ri 
All 1, 9 
M1 1, 
M2 158, 8 
File: HUSMC'S 7 
Patient 10: T AG= 
Gate: G1 
T eta I Events: 50 
Marker Left, Ri, 
All 1, 9~ 
M1 1, 
M2 158, 8· 
File: HUSMC'S . 
Patient ID: TAG: 
Gate: G1 
T etal Events: 5C 
Marker Left. R 
All 1, ~ 
M1 1, 
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Histogram Statistics 
File: HUSMC'S 7/24/01.009 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3423 
Marker Left. Right Events % Gated % Total Mean Peak Ch 
AJI 1. 9910 3423 100.00 68.46 1076.34 743 
M1 1, 158 1110 32.43 22.20 55.12 58 
M2 158, 8429 2271 66.35 45.42 1414.76 743 
Histogram Statistics 
File: HUSMC'S 7/24/01.009 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Sample 10: HUMAN AORTIC SMCS 
Acquismon Date: 24-Jul-1 
Gated Events: 3423 
Marker Lett. Right Events . % Gated % Total Mean PeakCh 
. 
All 1, 9910 3423 100.00 68.46 1044.53 610 
M1 1. 158 1103 32.22 22.06 56.41 42 
M2 158, 8429 2314 67.60 46.28 1478.12 610 
Histogram Statistics 
File: HUSMC'S 7/24/01.009 
Patient 10: TAG=TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3423 
M1 1. 158 1242 
M2 158, 8429 2186 
SafTlJle 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3423 
% Gated % Total Mean Peak Ch 
100.00 68.46 749.14 594 
36.28 24.84 45.22 46 
63.86 43.72 1147.73 594 
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Histogram Statistics 
File: HUSMC'S 7/24101.008 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left. Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3393 
Events % Gated % Total Mean 
3393 100.00 67.86 901.02 
1302 38.37 26.04 53.17 






File: HUSMC'S 7/24101.008 
Patient 10: TAG: TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3393 
Events % Gated % Total Mean 
3393 100.00 67.86 1020.62 
1174 34.60 23.48 74.79 






File: HUSMC'S 7/24101.008 
Patient 10: TAG=TUBE 
Gate: G1 
SafTllle 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jui-1 
Gated Events: 3393 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 3393 100.00 67.86 796.27 704 
M1 1, 158 1303 38.40 26.06 67.71 54 
M2 158, 8429 2091 61.63 41.82 1245.87 704 
Page 1 
















0 200 400 600 800 1000 
FSC-H 






















'::.e;r.+( 0 \ 
l-\ ~) Ao S ('(H~ 
c,.J) . ' ., { 01 
Histogram Statistics 
File: HUSMC'S 7/24/01.011 
Patient 10: TAG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTlC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left. Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3356 
Events % Gated % Total Mean 
3356 100.00 67.12 1046.29 
1115 33.22 22-30 59.1 0 






File: HUSMC'S 7/24/01.011 
Patient 10: TAG: TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 3356 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
AJI 1, 9910 3356 100.00 67.12 1014.18 813 
M1 1, 158 1116 33.25 22.32 59.18 38 
M2 158, 8429 2233 66.54 44.66 1460.51 813 
Histogram Statistics 
File: HUSMC'S 7/24/01.011 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3356 
M1 1, 158 1269 
M2 158, 8429 2090 
S~le 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Ju1-1 
Gated Events: 3356 
% Gated % Total Mean Peak Ch 
100.00 67.12 707.39 483 
37.81 25.38 44.55 18 
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Histogram Statistics 
File: VECTOR RED 6/21/01.001 
Patient 10: A 1 
Gate: G1 
Total Events: 10000 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 6389 
X Parameter: FL 1-H (Log) 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 6389 100.00 63.89 46.80 
46.81 
39 
39 M1 3, 470 6387 99.97 63.87 
Histogram Statistics 
File: VECTOR RED 6/21/01.001 
Patient 10: A1 
Gate: G1 
Total Events: 10000 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 6389 
X Parameter: FL2-H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 6389 100.00 63.89 84.33 53 
M1 3, 470 6387 99.97 63.87 84.20 53 
Histogram Statistics 
File: VECTOR RED 6/21/01.001 
Patient 10: A 1 
Gate: G1 
Total Events: 10000 
Marker Left, Right Events 
All 1, 9910 6389 
M1 3, 470 6234 





Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 6389 
X Parameter: FL3-H (Log) 
% Total Mean Peak Ch 
63.89 164.55 119 
62.34 153.49 119 
63.74 164.90 119 
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Histogram Statistics 
File: VECTOR RED 6/21/01.003 
Patient 10: A3 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 517 Gate: G1 
Total Events: 5190 X Parameter: FL 1-H (Log) 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1,9910 517 100.00 9.96 14.28 8 
M1 3, 470 513 99.23 9.88 14.37 8 
Histogram Statistics 
File: VECTOR RED 6/21/01.003 
Patient 10: A3 
Sample 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 517 Gate: G1 
Total Events: 5190 X Parameter: FL2-H (Log) 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 517 100.00 9.96 11.07 18 
M1 3, 470 494 95.55 9.52 11.49 18 
Histogram Statistics 
File: VECTOR RED 6/21/01.003 
Patient 10: A3 
S~mple 10: VECTOR RED 
Acquisition Date: 21-Jun-1 
Gated Events: 517 Gate: G1 
Total Events: 5190 X Parameter: FL3-H (Log) 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 517 100.00 9.96 17.83 18 
M1 3, 470 499 96.52 9.61 18.41 18 
M2 28, 2288 84 16.25 1.62 45.62 29 
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Histogram Statistics 
L' i, \ .~ 
File: HUSMCS 7/24101.004 
Patient 10: TAG: ll.JBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
\ !~, 
Gated Events: 3002 
T ota! Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 3002 100.00 60.04 1124.17 858 
M1 1, 289 970 32.31 19.40 79.62 50 
M2 289, 9910 2034 67.75 40.68 1621.49 858 
Histogram Statistics 
e'" Rle: HUSMC'S 7/24101.005 
t..;, :_ " it~ 
Patient 10: TAG:: ll.JBE 
.' , 
'I' 
-.. ~:./ Gate: G1 
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SarTl'le 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3479 
% Gated % Total Mean Peak Ch 
100.00 69.58 1398.67 1027 
23.91 16.64 87.29 




~. { .:.: 
File: HUSMC'S 7/24/01.006 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 2591 
M1 1, 289 1159 
M2 289, 9910 1433 
" -.:: . , /' 
.:~ c:. r ..... ~ .. , "",:- i 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2591 
% Gated % Total Mean Peak Ch 
100.00 51.82 778.40 578 
44.73 23.18 87 .16 51 
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Histogram Statistics 
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Rle: HUSMC'S 7/24/01.001 SarllJle 10: HUMAN AORTIC SMCS 
Patient 10: TAG= TUBE Acquisition Date: 24-Jul-1 
Gate: G1 Gated Events: 2133 
Total Events: 4425 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 2133 100.00 48.20 778.00 34 
M1 1, 289 1055 49.46 23.84 81.92 34 
M2 289, 9910 1082 50.73 24.45 1454.91 874 
Histogram Statistics 
Rle: HUSMC'S 7/24/01.002 
Patient 10: TAG= TUBE 
SarllJle 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gate: G1 \ G ,l\ l 1_(. -1 
Total Events: 4785 
Gated Events: 2757 
Marker Left, Right 
All 1, 9910 
M1 1, 289 









% Total Mean PeakCh 
57.62 976.76 813 
22.61 81.27 53 
35.01 1555.22 813 
Histogram Statistics 
File: HUSMC'S 7/24/01.003 
Patient 10: TAG=TUBE 
Gate: G1 
Total Events: 5235 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2905 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
2905 100.00 55.49 1046.99 
1094 
1813 
37.66 20.90 88.79 
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Histogram Statistics 
File: HUSMC'S 7/24/01.001 
Patient 10: TAG= TUBE 
Gate: No Gate 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 4425 
Total Events: 4425 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
4425 100.00 100.00 402.17 
3296 74.49 74.49 52.57 





File: HUSMC'S 7/24/01.002 Sample 10: HUMAN AORTIC SMC'S 
Patient 10: TAG= TUBE Acquisition Date: 24-Jul-1 
Gate: No Gate Gated Events: 4785 
l-.:: 'j Total Events: 4785 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 4785 100.00 100.00 584.11 53 
M1 1, 289 3060 63.95 63.95 53.41 53 
M2 289, 9910 1725 36.05 36.05 1525.53 583 
Histogram Statistics 
File: HUSMC'S 7/24/01.003 Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 S ,t{ '--. ___ ',J Patient ID: TAG= TUBE 
Gate: No Gate 
Total Events: 5235 
Gated Events: 5235 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1,9910 5235 100.00 100.00 604.34 23 
M1 1, 289 3374 64.45 64.45 57.51 23 
M2 289, 9910 1865 35.63 35.63 1592.94 667 
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Histogram Statistics 
Rle: HUSMCS 7/24101.010 
Patient 10: TAG=: TUBE 
Gate: No Gate 
SafllJle 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 5000 
C, I • I \,ji(... Total Events: 5000 
J ."'\. .... 
'2 • .. . 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 5000 100.00 100.00 687.22 . 851 
M1 1, 289 2927 58.54 58.54 56.78 49 
M2 289, 9910 2077 41.54 41.54 1574.89 851 
Histogram Statistics 
Rle: HUSMC'S 7/24101.011 
Patient 10: TAG: TUBE 
Gate: No Gate 
Sarrple 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
Gated Events: 5000 
Events % Gated % Total 
5000 100.00 100.00 










File: HUSMC'S 7/24101.012 
Patient 10: T AG= TUBE 
Gate: No Gate 
Sample 10: HUMAN AORTlC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 5000 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 5000 100.00 100.00 593.30 40 
M1 1, 289 3253 65.06 65.06 53.45 40 







































File: HUSMC'S 7 



















o HUSMC'S 7/24101 .012 
o 
o .c ... . , ;;.. 
• : , ' • -_' f ' I '~..;"": 
o 200 400 600 8001000 
FSC-H 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3079 
% Gated % Total Mean Peak Ch 
100.00 61.58 1084.18 851 
34.10 21.00 87.17 45 
65.96 40.62 1598.84 851 
11~'ti"'I"t,.~rn Statistics 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3019 
% Gated % Total Mean Peak Ch 
100.00 60.38 1116.03 813 
32.99 19.92 89.03 
67.11 40.52 1619.69 
49 
813 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2752 
% Gated % Total Mean 
100.00 55.04 1035.76 
38.37 21.12 80.99 
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"df):; ,t), L VlL File: HUSMC'S 7/24/01.007 
Patient 10: TAG= TUBE 
Gate: G1 
Sarrple ID: HUMAN AORTIC.SMCS 
..... ftl! . 
Acquisition Date: 24-Jul-l r ',-
Gated Events: 2181 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean 
All 1, 9910 2181 100.00 43.62 1243.24 
M1 1, 289 364 16.69 7.28 
M2 289, 9910 1830 83.91 36.60 
Histogram Statistics 
File: HUSMC'S 7/24/01.008 
SO ,v, l '1R Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3042 
M1 1, 289 1105 
M2 289, 9910 1940 
Acquisition Date: 
Gated Events: 3042 
".: ' , 
% Gated % Total Mean 
100.00 60.84 1125.72 
36.32 22.10 108.28 
63.77 38.80 1703.94 
. Histogram Statistics 
Rle: HUSMC'S 7/24/01.009 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3120 
M1 1, 289 1011 
M2 289, 9910 2110 
Sample 10: HUMAN 
Gated Events: 3120 
% Gated % Total Mean 
100.00 62.40 1137.90 
32.40 20.22 88.81 
67.63 42.20 1640.16 


























































File: HUSMC'S 7/24101.004 
Patient 10: TAG= TUBE 
Gate: No Gate 
Sample 10: HUMAN AORTIC SMC'S 




~. . ."" 
~"'\ " 
.... . ::.; ', 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 289 
M2 289, 9910 
Gated Events: 5000 
Events % Gated % Total 
5000 100.00 100.00 










Rle: HUSMC'S 7/24/01.005 
Patient 10: TAG= TUBE 
Gate: No Gate 
SaJ'l1)le 10: HUMAN AORTIC SMC'S 
~ Acquisition Date: 24-Jul-1 
Gated Events: 5000 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 5000 100.00 100.00 989.87 1027 
M1 1, 289 2301 46 .02 46.02 56.01 29 
~ 289, 9910 2701 54.02 54.02 1784.91 1027 
'., ~ r ," 
Histogram Statistics 
File: HUSMC'S 7/24101.006 
Patient 10: TAG= TUBE 
Gate: No Gate 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 5000 
M1 1, 289 3492 
M2 289, 9910 1509 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 5000 
% Gated % Total Mean Peak Ch 
100.00 100.00 429.38 578 
69.84 69.84 55.75 28 
30.18 30.18 1293.91 578 
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So JAl ~ \..t,,, 
Histogram Statistics 
File: HUSMC'S 7/24/01.001 
Patient 10: TAG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 4425 
Marker Left, Rig ht 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 2494 
Events % Gated % Total Mean 
2494 100.00 56.36 70929 
1212 48.60 27.39 55.80 






File: HUSMCS 7/24/01.001 
Patient 10: TAG= ruBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 2494 
Total Events: 4425 
Marker Left, Right Events % Gated % Total Mean PeakCh 
All 1, 9910 2494 100.00 56.36 680.25 34 
M1 1, 158 1228 49.24 27.75 55.72 34 
M2 158, 8429 1262 50.60 28.52 1243.00 874 
Histogram Statistics 
File: HUSMC'S 7/24101.001 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 4425 
Marker Left, Right Events 
All 1 J 9910 2494 
M1 1, 158 1356 
M2 158, 8429 1139 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2494 
% Gated % Total Mean Peak Ch 
100.00 56.36 495.12 52 
54.37 30.64 41.29 52 
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Histogram Statistics 
File: HUSMC'S 7/24101.004 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3294 
M1 1, 158 1087 
M2 158, 8429 2160 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3294 
% Gated % Total Mean Peak Ch 
100.00 65.88 1079.18 9140 
33.00 21.74 54.24 43 
65.57 43.20 1418.84 843 
Histogram Statistics 
File: HUSMC'S 7/24101.004 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3294 
M1 1, .158 1094 
M2 158, 8429 2192 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 3294 
% Gated % Total Mean PeakCh 
100.00 65.88 1031.80 858 
33.21 21.88 53.94 50 
66.55 43.84 1477.19 858 
Histogram Statistics 
File: HUSMC'S 7/24/01.004 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 3294 
M1 1, 158 1206 
M2 158, 8429 2090 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3294 
% Gated % Total Mean Peak Ch 
100.00 65.88 732.91 632 
36.61 24.12 39.99 55 
63.45 41.80 1132.19 632 
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Histogram Statistics 
File: HUSMC'S 7/24/01 .005 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Lett. Right 
All 1, 9910 
M1 1, 158 























File: HUSMC'S 7/24/01.005 
Patient 10: T AG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Total Events: 5000 
Marker Left, Right 
All 1, 9910 
M1 1, 158 
M2 158, 8429 
Gated Events: 3739 
Events % Gated % Total Mean 
3739 100.00 74.78 1307.94 
911 24.36 18.22 56.64 






File: HUSMC'S 7/24/01.005 
Patient 10: TAG= TUBE 
Gate: G1 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 3739 
Total Events: 5000 
Marker Left, Right Events % Gated % Total Mean Peak Ch 
All 1, 9910 3739 100.00 74.78 935.87 661 
M1 1, 158 1027 27.47 20.54 43.42 43 
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Histogram Statistics 
File: HUSMC'S 7/24/01.006 
Patient 10: T AG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
AJI 1, 9910 2975 
M1 1, 158 1305 
M2 158, 8429 1659 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2975 
% Gated % Total Mean PeakCh 
100.00 59.50 701.59 542 
43.87 26.10 56.71 39 
55.76 33.18 1127.21 542 
Histogram Statistics 
File: HUSMC'S 7/24101.006 
Patient 10: TAG= TUBE 
Gate: G1 
Total Events: 5000 
Marker Left, Right Events 
All 1, 9910 2975 
M1 1, 158 1313 
M2 158, 8429 1664 
Sample 10: HUMAN AORTIC SMCS 
Acquisition Date: 24-Jul-1 
Gated Events: 2975 
% Gated % Total Mean PeakCh 
100.00 59.50 689.03 578 
44.13 26.26 57.19 36 
55.93 33.28 1166.88 578 
Histogram Statistics 
File: HUSMC'S 7/24/01.006 
Patient 10: TAG= TUBE 
Gate: G1 
T otai Events: 5000 
. Marker Left, Right Events 
All 1, 9910 2975 
M1 1, 158 1474 
M2 158, 8429 1503 
Sample 10: HUMAN AORTIC SMC'S 
Acquisition Date: 24-Jul-1 
Gated Events: 2975 
% Gated % Total Mean Peak Ch 
100.00 59.50 487.56 496 
49.55 29.48 43.73 47 












530 nM (FITC) 
585 nM: PI/PE 
>650 nM: RED 
525 NM 575 NM 
